Total pharma deals worth $21.11bn were announced during Q4 2018, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
Go deeper with GlobalData
The value marked a decrease of 6.32% over the previous quarter and a drop of 64.84% when compared with the last four-quarter average of $60.07bn.
In terms of number of deals, the sector saw a drop of 7.18% over the last four-quarter average with 388 deals against the average of 418 deals.
In value terms, North America led the activity with deals worth $16.64bn.
The top announced deal, as tracked by GlobalData, in Q4 2018 was GlaxoSmithKline’s $5.1bn acquisition of TESARO.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe article considers only announced and completed deals from the GlobalData Financial Deals database and excludes all terminated and rumoured deals. GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
